Corpus ID: 2584964

Treatment of severe acute respiratory syndrome with convalescent plasma.

@article{Wong2003TreatmentOS,
  title={Treatment of severe acute respiratory syndrome with convalescent plasma.},
  author={Vincent Wai‐Sun Wong and D Dai and A K L Wu and Joseph J. Y. Sung},
  journal={Hong Kong medical journal = Xianggang yi xue za zhi},
  year={2003},
  volume={9 3},
  pages={
          199-201
        }
}
  • V. Wong, D. Dai, +1 author J. Sung
  • Published 2003
  • Medicine
  • Hong Kong medical journal = Xianggang yi xue za zhi
In March 2003, an outbreak of severe acute respiratory syndrome started in Hong Kong. A 57-year-old woman had a typical presentation, including fever, non-productive cough, malaise, lymphopenia, and raised liver aminotransferases. The clinical course and successful treatment with convalescent plasma, ribavirin, and corticosteroids are discussed. 

Paper Mentions

Interventional Clinical Trial
A randomized, open-label, multicenter, three-arm clinical trial to study the efficacy and safety of passive immunotherapy (convalescent plasma and anti-COVID-19 human immunoglobulin… Expand
ConditionsCoronavirus Disease 2019 (COVID-19)
InterventionBiological, Drug
Interventional Clinical Trial
This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive… Expand
ConditionsCovid19, SARS-Associated Coronavirus, SARS-CoV Infection
InterventionBiological
Treatment of severe acute respiratory syndrome with convalescent plasma.
The medical rationale behind the use of convalescent plasma that potentially contains neutralising immunoglobulin (Ig) G or M is to decrease the viral load and to control viraemia symptoms. A similarExpand
Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma
TLDR
Human SARS hyperimmune globulins for intravenous (IV) injection were purified in this study for more effective treatment and prevention of SARS. Expand
Severe Acute Respiratory Syndrome
TLDR
An overview of the epidemiology, clinical presentation, diagnosis, and treatment of SARS based on the current state of knowledge derived from published studies and the own personal experience is presented. Expand
Treating severe acute respiratory syndrome with hyperimmune globulins.
  • M. Ali
  • Medicine
  • Hong Kong medical journal = Xianggang yi xue za zhi
  • 2003
TLDR
A virus-inactivated, purified, and concentrated immunoglobulin (Ig) preparation obtained by the fractionation of a large pool of convalescent plasma could be developed for clinical evaluation and use for two reasons: its use would limit the risks of exposing patients to blood-borne viral infections. Expand
Suggested management of immunocompromized kidney patients suffering from SARS
  • M. Chiu
  • Medicine
  • Pediatric Nephrology
  • 2003
TLDR
Paediatric nephrologists should be on the alert for SARS in order to care for immunocompromised patients and Precautions should be made for both staff and patients with protective measures for infection control. Expand
The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study
TLDR
CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases, but the optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials. Expand
Treatment of severe acute respiratory syndrome
TLDR
When patients deteriorate clinically despite treatment with ribavirin and corticosteroids, rescue treatment with convalescent plasma and immunoglobulin may be beneficial, and interferons and other novel agents may hold promise as useful anti-SARS therapies in the future. Expand
Treating emerging viral infections.
  • K. Chow
  • Medicine
  • Hong Kong medical journal = Xianggang yi xue za zhi
  • 2003
TLDR
The therapeutic use of serum products in managing infectious disease reminds us of the pioneering work of Robert Koch’s students, who developed a sheep antiserum against diphtheria toxin in 1891, and the strategy of administering plasma from survivors of various epidemics of viral illness has been used with success. Expand
Severe acute respiratory syndrome in a medical center in Taipei.
TLDR
Fever followed by rapidly progressive respiratory compromise led to significant morbidity and mortality in this cohort of patients with probable severe acute respiratory syndrome. Expand
Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections.
  • T. Tong
  • Medicine
  • Infectious disorders drug targets
  • 2009
TLDR
The high mortality of SARS, the identification of a natural reservoir, and the well-founded fear of provoking antibody-enhanced disease as a result of vaccination fueled the ongoing efforts in anti-coronavirus drug discovery, presenting the results of current research. Expand
...
1
2
3
4
...

References

SHOWING 1-3 OF 3 REFERENCES
A cluster of cases of severe acute respiratory syndrome in Hong Kong.
TLDR
SARS appears to be infectious in origin, and Fever followed by rapidly progressive respiratory compromise is the key complex of signs and symptoms from which the syndrome derives its name. Expand
Identification of severe acute respiratory syndrome in Canada.
TLDR
SARS appears to be of viral origin, with patterns suggesting droplet or contact transmission, and the role of human metapneumovirus, a novel coronavirus, or both requires further investigation. Expand
Quasispecies, error catastrophe, and the antiviral activity of ribavirin.
TLDR
The data supporting this new proposal for the mechanism of action of ribavirin are reviewed and the challenges that remain for development of lethal mutagenesis as an effective antiviral strategy are discussed. Expand